Pfizer’s Braftovi to command 42 per cent share of BRAF inhibitors melanoma market by 2028:… EP News Bureau Mar 21, 2024 GlobalData’s patient-based forecast reveals that the BRAF inhibitor market for melanoma will reach a key milestone by 2028, with…
